ctDNA guiding adjuvant immunotherapy in urothelial carcinomaThomas Powles, Sanjeev Mariathasan, Shruti Sharma et al.|Nature|2021Cited by 603
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 studyArjun Vasant Balar, Ronald de Wit, Ashish M. Kamat et al.|The Lancet Oncology|2021Cited by 532
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trialJoaquim Bellmunt, Thomas Powles, Maha Hussain et al.|The Lancet Oncology|2021Cited by 411
Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial CarcinomaThomas Powles, Sanjeev Mariathasan, Zoe J. Assaf et al.|European Urology|2023Cited by 128
Sensitizing Effect of Galectin-7 in Urothelial Cancer to Cisplatin through the Accumulation of Intracellular Reactive Oxygen SpeciesYoshiyuki Matsui, Hiroyuki Nishiyama|Cancer Research|2007Cited by 53